Zacks Research Analysts Lower Earnings Estimates for CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities research analysts at Zacks Research reduced their Q3 2025 earnings per share (EPS) estimates for Corcept Therapeutics in a report issued on Tuesday, January 21st. Zacks Research analyst K. Das now forecasts that the biotechnology company will post earnings per share of $0.41 for the quarter, down from their previous forecast of $0.42. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ FY2025 earnings at $1.56 EPS.

Several other equities analysts have also recently weighed in on the stock. Truist Financial increased their price objective on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a research note on Monday, September 30th. StockNews.com downgraded Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Sandler O’Neill restated a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Corcept Therapeutics has a consensus rating of “Buy” and an average target price of $65.25.

Corcept Therapeutics Price Performance

Shares of CORT opened at $62.29 on Friday. The firm has a market cap of $6.53 billion, a PE ratio of 49.44 and a beta of 0.56. Corcept Therapeutics has a 1-year low of $20.84 and a 1-year high of $62.98. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $54.85 and a two-hundred day simple moving average of $45.44.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.14. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm had revenue of $182.55 million during the quarter, compared to analysts’ expectations of $171.97 million. During the same quarter in the previous year, the business earned $0.28 earnings per share. The company’s revenue was up 47.7% on a year-over-year basis.

Institutional Investors Weigh In On Corcept Therapeutics

Hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP raised its position in Corcept Therapeutics by 4.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,676,335 shares of the biotechnology company’s stock worth $86,952,000 after purchasing an additional 108,658 shares during the period. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Corcept Therapeutics in the second quarter worth approximately $205,000. Hsbc Holdings PLC lifted its stake in shares of Corcept Therapeutics by 34.5% during the 2nd quarter. Hsbc Holdings PLC now owns 108,366 shares of the biotechnology company’s stock worth $3,479,000 after acquiring an additional 27,785 shares during the last quarter. Intech Investment Management LLC purchased a new position in Corcept Therapeutics during the 2nd quarter valued at $468,000. Finally, Evergreen Capital Management LLC bought a new position in Corcept Therapeutics in the 2nd quarter valued at $217,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Insiders Place Their Bets

In other news, insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total value of $1,007,800.00. Following the transaction, the insider now owns 85,318 shares of the company’s stock, valued at approximately $4,299,174.02. The trade was a 18.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.88, for a total transaction of $131,736.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,011 shares of company stock worth $1,951,268. Corporate insiders own 20.50% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.